Milestone Pharmaceuticals Inc — datos financieros trimestrales (NASDAQ:MIST) | MetaTrader

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Flujo de caja de las actividades operativas -6.84 M-13.95 M-12.57 M-9.75 M-12.78 M -49.04 M Flujo de caja de las actividades de inversión 19.33 M33.58 M9.94 M-34.98 M2.7 M 11.25 M Flujo de caja de las actividades financieras 24 K140 K36 K48.92 M36.43 M 85.53 M Flujo de caja libre -6.87 M-13.96 M-12.58 M-9.75 M-13.06 M -49.34 M

Noticias

Milestone Pharmaceuticals planea estudio de registro PSVT del mundo real

Raymond James inicia cobertura de Milestone Pharmaceuticals con recomendación de Compra Fuerte

Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript

Milestone Pharmaceuticals cumple previsión de BPA, acción cae

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Stock: Downgrading To Sell As CARDAMYST Faces A Tough Reality (NASDAQ:MIST)

Milestone Pharmaceuticals appoints David Sandoval as general counsel

All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy

Tratamiento CARDAMYST de Milestone para PSVT ya disponible en farmacias de EE.UU.

El tratamiento CARDAMYST de Milestone para TPSV ya disponible en farmacias de EE.UU.

Milestone’s PSVT treatment CARDAMYST now available in US pharmacies

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)